A long-term pilot study of pipothiazine palmitate in chronic schizophrenia.
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D010169:Palmitic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010640:Phenothiazines; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D012562:Schizophrenia, Disorganized / Q000188:drug therapy; D012563:Schizophrenia, Paranoid / Q000188:drug therapy; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014476:Undecylenic Acids / Q000627:therapeutic use
D014150:Antipsychotic Agents; D010169:Palmitic Acids; D010640:Phenothiazines; D010880:Piperidines; D013449:Sulfonamides; D014476:Undecylenic Acids